A phase I study of BMS-354825 [dasatinib] in patients with solid tumors.
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2010
At a glance
- Drugs Dasatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 14 Dec 2010 Actual patient number is 16 according to ClinicalTrials.gov.
- 08 Dec 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.